For decades, great strides have been made in the field of immunometabolism. A plethora of
evidence ranging from basic mechanisms to clinical transformation has gradually embarked …

Immune checkpoint blockade (ICB) therapy works by inhibiting suppressive checkpoints that
become upregulated after T cell activation, like PD-1/PD-L1 and CTLA-4. While the initial …

Immune checkpoint inhibition treatment using aPD-1 monoclonal antibodies is a promising
cancer immunotherapy approach. However, its effect on tumor immunity is narrow, as most …

The DNA exonuclease three-prime repair exonuclease 1 (TREX1) is critical for preventing
autoimmunity in mice and humans by degrading endogenous cytosolic DNA, which …

In recent years, research focused on the multifaceted landscape and functions of cancer-
associated fibroblasts (CAFs) aimed to reveal their heterogeneity and identify commonalities …

The immunosuppressive tumor immune microenvironment and low tumor immunogenicity
invariably subvert the efficacy of cancer vaccine and the antitumor immunity. An alternative …

Purpose: CD137 is a T-and NK-cell costimulatory receptor involved in consolidating
immunologic responses. The potent CD137 agonist urelumab has shown clinical promise as …

T cells are often absent from human cancer tissues during both spontaneously induced
immunity and therapeutic immunotherapy, even in the presence of a functional T cell …

Cancer progression can be restrained by tumor‐infiltrating lymphocytes in a process termed
cancer immunosurveillance. Based on how lymphocytes are activated and recruited to the …

Blood vessels are a key target for cancer therapy. Compared with the healthy vasculature,
tumor blood vessels are extremely immature, highly permeable, and deficient in pericytes …